Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/DDR1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/DDR1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/DDR1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/DDR1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/DDR1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/DDR1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/DDR1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/DDR1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0061138 | Colorectum | MSS | morphogenesis of a branching epithelium | 51/3467 | 182/18723 | 1.06e-03 | 1.05e-02 | 51 |
GO:00075892 | Colorectum | MSS | body fluid secretion | 29/3467 | 93/18723 | 2.21e-03 | 1.84e-02 | 29 |
GO:00485881 | Colorectum | MSS | developmental cell growth | 61/3467 | 234/18723 | 2.56e-03 | 2.03e-02 | 61 |
GO:00605601 | Colorectum | MSS | developmental growth involved in morphogenesis | 61/3467 | 234/18723 | 2.56e-03 | 2.03e-02 | 61 |
GO:0060444 | Colorectum | MSS | branching involved in mammary gland duct morphogenesis | 10/3467 | 22/18723 | 3.42e-03 | 2.56e-02 | 10 |
GO:0060603 | Colorectum | MSS | mammary gland duct morphogenesis | 12/3467 | 30/18723 | 5.00e-03 | 3.46e-02 | 12 |
GO:1990138 | Colorectum | MSS | neuron projection extension | 45/3467 | 172/18723 | 8.06e-03 | 4.91e-02 | 45 |
GO:00487323 | Colorectum | MSI-H | gland development | 53/1319 | 436/18723 | 7.08e-05 | 2.35e-03 | 53 |
GO:00336743 | Colorectum | MSI-H | positive regulation of kinase activity | 53/1319 | 467/18723 | 3.99e-04 | 8.98e-03 | 53 |
GO:00420603 | Colorectum | MSI-H | wound healing | 47/1319 | 422/18723 | 1.23e-03 | 2.00e-02 | 47 |
GO:00108103 | Colorectum | MSI-H | regulation of cell-substrate adhesion | 28/1319 | 221/18723 | 1.83e-03 | 2.63e-02 | 28 |
GO:00224113 | Colorectum | MSI-H | cellular component disassembly | 47/1319 | 443/18723 | 3.26e-03 | 3.99e-02 | 47 |
GO:00508783 | Colorectum | MSI-H | regulation of body fluid levels | 41/1319 | 379/18723 | 4.10e-03 | 4.67e-02 | 41 |
GO:002241120 | Esophagus | HGIN | cellular component disassembly | 102/2587 | 443/18723 | 8.31e-08 | 4.33e-06 | 102 |
GO:004873225 | Esophagus | HGIN | gland development | 88/2587 | 436/18723 | 1.34e-04 | 2.71e-03 | 88 |
GO:001604919 | Esophagus | HGIN | cell growth | 93/2587 | 482/18723 | 4.49e-04 | 6.62e-03 | 93 |
GO:000155818 | Esophagus | HGIN | regulation of cell growth | 76/2587 | 414/18723 | 5.40e-03 | 4.42e-02 | 76 |
GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
GO:0016049110 | Esophagus | ESCC | cell growth | 289/8552 | 482/18723 | 1.29e-10 | 3.77e-09 | 289 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DDR1 | SNV | Missense_Mutation | | c.1852N>C | p.Glu618Gln | p.E618Q | Q08345 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
DDR1 | SNV | Missense_Mutation | rs527938479 | c.1826N>A | p.Arg609Gln | p.R609Q | Q08345 | protein_coding | tolerated(0.69) | benign(0.019) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
DDR1 | SNV | Missense_Mutation | novel | c.1438G>A | p.Glu480Lys | p.E480K | Q08345 | protein_coding | tolerated(0.82) | benign(0.291) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DDR1 | SNV | Missense_Mutation | rs370113205 | c.1696N>A | p.Val566Ile | p.V566I | Q08345 | protein_coding | tolerated(0.06) | probably_damaging(0.964) | TCGA-D8-A1X6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
DDR1 | SNV | Missense_Mutation | novel | c.571C>T | p.Leu191Phe | p.L191F | Q08345 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-E2-A574-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
DDR1 | deletion | Frame_Shift_Del | novel | c.949delN | p.Met318CysfsTer5 | p.M318Cfs*5 | Q08345 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
DDR1 | SNV | Missense_Mutation | rs557271556 | c.586G>A | p.Ala196Thr | p.A196T | Q08345 | protein_coding | tolerated(0.09) | benign(0.192) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DDR1 | SNV | Missense_Mutation | rs370297461 | c.2282G>A | p.Arg761His | p.R761H | Q08345 | protein_coding | deleterious(0) | probably_damaging(0.91) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DDR1 | SNV | Missense_Mutation | novel | c.2569G>A | p.Glu857Lys | p.E857K | Q08345 | protein_coding | deleterious(0) | possibly_damaging(0.699) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
DDR1 | SNV | Missense_Mutation | rs776556090 | c.2648N>T | p.Pro883Leu | p.P883L | Q08345 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A2LV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 381118865 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | US9567304, Compound N-9 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | VAPBGCRAUJRZPO-UHFFFAOYSA-N | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | BDBM50080408 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | US9695118, 4 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | | NG7 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 328083456 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 178102314 | IMATINIB | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 252827391 | | |
780 | DDR1 | DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 363894135 | MERESTINIB | |